Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Pasithea Therapeutics Corp. Warrant (KTTAW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/09/2025: KTTAW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -95.24% | Avg. Invested days 9 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/09/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.34 | 52 Weeks Range 0.01 - 0.10 | Updated Date 06/6/2025 |
52 Weeks Range 0.01 - 0.10 | Updated Date 06/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -46.84% | Return on Equity (TTM) -82.81% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 6931236 |
Shares Outstanding - | Shares Floating 6931236 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Pasithea Therapeutics Corp. Warrant
Company Overview
History and Background
Pasithea Therapeutics Corp. Warrant (PASW) represents the right to purchase shares of Pasithea Therapeutics Corp. (pasw). Pasithea Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer and autoimmune diseases. The company was incorporated in 2019. Significant milestones would relate to the underlying company's clinical trial progress and regulatory filings.
Core Business Areas
- Oncology: Development of targeted therapies for various types of cancer.
- Autoimmune Diseases: Research and development of treatments for autoimmune conditions.
Leadership and Structure
Information on the leadership team and specific organizational structure for the warrant itself is not directly applicable. Leadership and structure would pertain to the underlying company, Pasithea Therapeutics Corp. (pasw), which has a management team and board of directors responsible for its operations and strategic direction.
Top Products and Market Share
Key Offerings
- Product Name 1: Pasithea Therapeutics' lead drug candidates are in development. Specific product names and their market share are not yet established as they are in clinical stages. Competitors vary widely depending on the specific therapeutic area being pursued.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful drug discoveries. The focus on oncology and autoimmune diseases places Pasithea Therapeutics within two of the largest and most dynamic segments of the pharmaceutical market.
Positioning
Pasithea Therapeutics Corp. Warrant's positioning is tied to the success and progress of the underlying company's drug development pipeline. Its competitive advantage, if any, would stem from the novelty of its scientific approach and the potential efficacy of its investigational therapies.
Total Addressable Market (TAM)
The TAM for oncology and autoimmune disease treatments is vast, measured in hundreds of billions of dollars globally. Pasithea Therapeutics, as a clinical-stage company, is positioned to capture a fraction of this TAM if its lead candidates achieve regulatory approval and commercial success. Its current market share is negligible as it has no approved products.
Upturn SWOT Analysis
Strengths
- Focus on high-need therapeutic areas (oncology, autoimmune diseases).
- Potential for disruptive innovation in drug development.
Weaknesses
- Clinical-stage company with no approved products, leading to high risk.
- Reliance on successful clinical trials and regulatory approvals.
- Limited financial resources compared to established pharmaceutical giants.
Opportunities
- Advancements in personalized medicine and targeted therapies.
- Growing demand for innovative treatments for cancer and autoimmune diseases.
- Potential for strategic partnerships and collaborations.
Threats
- Failure to demonstrate efficacy or safety in clinical trials.
- Intense competition from established pharmaceutical companies and other biotechs.
- Stringent regulatory hurdles and lengthy approval processes.
- Patent expirations of competitor drugs creating market shifts.
Competitors and Market Share
Key Competitors
- Pfizer Inc. (PFE)
- Merck & Co., Inc. (MRK)
- Bristol Myers Squibb Company (BMY)
- Roche Holding AG (RHHBY)
- Eli Lilly and Company (LLY)
Competitive Landscape
Pasithea Therapeutics Corp. faces intense competition from large, well-established pharmaceutical companies with significant R&D budgets, established sales forces, and diverse product portfolios. Its potential advantage lies in developing novel therapies with differentiated mechanisms of action that can address unmet medical needs.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for Pasithea Therapeutics Corp. Warrant is tied to the progress and valuation changes of Pasithea Therapeutics Corp. (pasw). This growth would be characterized by milestones in preclinical and clinical development.
Future Projections: Future projections are highly speculative and depend on the successful progression of Pasithea Therapeutics Corp.'s (pasw) drug candidates through clinical trials and into commercialization. Analyst estimates, if available, would focus on the potential peak sales of its pipeline drugs.
Recent Initiatives: Recent initiatives would pertain to Pasithea Therapeutics Corp. (pasw), such as initiating new clinical trials, reporting trial data, seeking regulatory designations, or entering into strategic partnerships.
Summary
Pasithea Therapeutics Corp. Warrant is a high-risk, high-reward investment tied to the success of its underlying biopharmaceutical company. The company operates in promising therapeutic areas but faces significant hurdles in clinical development and regulatory approval. Its strengths lie in its focus on innovation, while its weaknesses include its early-stage status and limited resources. Success hinges on breakthroughs in its pipeline.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC EDGAR)
- Financial data providers (e.g., Refinitiv, Bloomberg - access not available for direct data retrieval in this format)
- Industry analysis reports
Disclaimers:
This JSON output is a structured representation of information about Pasithea Therapeutics Corp. Warrant and its underlying company, Pasithea Therapeutics Corp. It is not financial advice. All information is subject to change and should be verified with official sources. Market share data is illustrative and based on general industry knowledge for the named competitors, not specific to Pasithea's current pipeline focus.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pasithea Therapeutics Corp. Warrant
Exchange NASDAQ | Headquaters Miami Beach, FL, United States | ||
IPO Launch date 2021-09-15 | CEO & Director Dr. Tiago Reis Marques M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://www.pasithea.com |
Full time employees 4 | Website https://www.pasithea.com | ||
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.